Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide in non-metastatic castration-resistant prostate cancer
2023-509221-47-00Phase 3Authorised
- Sponsor
- Aragon Pharmaceuticals
- Start
- Feb 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in castration-resistant prostate cancer (CRPC) comparing Apalutamide with Placebo (2 arms). Primary endpoint: Metastasis-Free Survival. Planned start Feb 2014; status: authorised.
02
Drugs
apalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2023-509221-47-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509221-47-00.